Disruption of components in the transforming growth factor-b (TGF-b) signalling cascade is a common occurrence in human cancers. TGF-b pathway activation is accomplished via serine/threonine kinase receptors and intracellular Smad transcription factors. A key regulatory step involves specific ubiquitination by Smurfs that mediate the proteasomal degradation of Smads and/or receptors. Here, we report a novel interaction between Smads and ubiquitin C-terminal hydrolase UCH37, a deubiquitinating enzyme that could potentially reverse Smurf-mediated ubiquitination. In GST pull down experiments, UCH37 bound weakly to Smad2 and Smad3, and bound very strongly to Smad7 in a region that is distinct from the -PY-motif in Smad7 that interacts with Smurf ubiquitin ligases. Endogenous Smad7 and UCH37 formed a stable complex in U4A/JAK1 cells, and FLAG-Smad7 co-immunoprecipitated with HA-UCH37 in transfected HEK-293 cells. In addition, we show that UCH37 can deubiquitinate and stabilize the type I TGF-b receptor. Furthermore, overexpression of UCH37 upregulates TGF-b-dependent transcription, and this effect is reversed in cells subject to RNAi-mediated knockdown of endogenous UCH37. These findings support a new role for deubiquitinating enzymes in the control of the TGF-b signalling pathway, and provide a novel molecular target for the design of inhibitors with therapeutic potential in cancer.
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Oncogene ( Keywords: transforming growth factor-b; Smads; ubiquitin Aberrant TGF-b signalling is responsible for a number of developmental disorders, human cancers, and fibrotic diseases. The TGF-b superfamily transmits signals via cell surface serine/threonine kinase receptors and intracellular Smad transcription factors (Shi and Massague, 2003) . Smads are segregated into three functional groups. R-Smads (Smads-1, 2, 3, and 5) are directly phosphorylated and activated by the TGF-b receptor complex. Co-Smad (Smad4) associates with activated R-Smads, and these heteromeric complexes are translocated to the nucleus where they regulate gene transcription by either association with DNA-binding proteins or direct binding to promoter sequences in target genes. I-Smads (Smads 6 and 7) inhibit Smad-mediated signalling and transcription.
Downregulation of TGF-b signalling is affected, in part, by a feedback mechanism that involves specific protein ubiquitination and proteasomal degradation of Smads and receptors. Ubiquitination plays a key role in a number of biological processes including signal transduction, cell cycle, and gene expression (Glickman and Ciechanover, 2002) . Recently, ubiquitin ligases known as Smurfs have been shown to bind to Smads and have been implicated in their specific ubiquitination. Smurf1 can interact selectively with Smad1 (Bone morphogenic protein pathway-specific), and this mechanism appears to regulate the abundance of Smad1 in unstimulated cells since it is not affected by receptor activation (Zhu et al., 1999) . Activated Smad2 is targeted for ubiquitin-mediated proteasomal degradation by Smurf2 in the nucleus (Lo and Massague, 1999) . In all cases, a small region in Smurfs known as a WW domain is responsible for the interaction with a -ProPro-X-Tyr-sequence motif in Smads. Interestingly, Smurfs also bind to inhibitory I-Smads. Following prolonged exposure of cells to TGF-b, the Smad7/ Smurf complex forms, exits the nucleus, and binds to the activated TGF-b receptor complex; the associated Smurf then ubiquitinates the receptor, thereby leading to its rapid degradation (Kavsak et al., 2000; Ebisawa et al., 2001; Suzuki et al., 2002) .
The conjugation of ubiquitinated substrates can be reversed by deubiquitinating enzymes (DUBs) that specifically cleave the isopeptide bond at the C-terminus of ubiquitin (Glickman and Ciechanover, 2002; Wing, 2003) . Most DUBs are members of either of two families of cysteine proteases: the ubiquitin-specific processing proteases (UBPs) and the ubiquitin C-terminal hydrolases (UCHs). There are emerging roles for DUBs in cell growth, oncogenesis, development, memory, and transcriptional regulation. For example, the human UBP known as HAUSP/USP7 (herpesvirus-associated ubiquitin-specific protease) was found to specifically deubiquitinate and stabilize the p53 tumour suppressor protein (Li et al., 2002) . BAP1 (BRCA1-associated protein 1) is a novel UCH enzyme that was found to interact with BRCA1 and enhance BRCA1-mediated growth suppression (Jensen et al., 1998) .
Here, we demonstrate a unique role for ubiquitin C-terminal hydrolase UCH37, also known as UCHL5 in mouse, in TGF-b signalling. Our results suggest that competing effects of ubiquitin ligases and deubiquitinating enzymes in complex with Smad7, in particular, could play a central role in fine-tuning cellular responses to TGF-bs under various physiological and pathological conditions.
To identify proteins that interact with MHI and linker regions of Smad3, we performed a yeast two-hybrid screen using a mouse brain library and Smad3 1-240 as bait. From 65 positive colonies displaying growth on selection media as well as b-galactosidase activity, we selected mouse UCHL5, also known as UCH37 in humans, for further study. UCH37 was first identified as a component of the 26S proteasome that is thought to be involved in the editing of polyubiquitinated protein substrates (Lam et al., 1997a, b) . It is a member of a family of UCH enzymes that have a conserved catalytic domain and, in some instances, have a nonconserved extended C-terminal tail ( Figure 1a ). Human UCH37 and mouse UCHL5 are 99% identical. BRCA1-associated protein BAP1 and UCH37 are unique in that they have an extended C-terminal tail, and in BAP1 this region contains the BRCA1 interaction domain. Proteosome-associated UCH37 removes ubiquitin sequentially from the distal end of the Lys48-linked polyubiquitin chain and can potentially rescue ubiquitinated substrates from proteasomal degradation. Since recent reports have elucidated an important role for Smurf ubiquitin ligases in the regulation of Smad signalling (Zhu et al., 1999; Lo and Massague, 1999; Kavsak et al., 2000; Ebisawa et al., 2001; Suzuki et al., 2002) , we hypothesized that UCH37 could potentially reverse Smurf-mediated ubiquitination and play an important role in the control of Smad/TGF-b signalling activity.
Initially, to verify the interaction of UCH37 with Smad3 as well as other Smads, we performed GST pull down experiments using lysates from cells expressing HA-tagged UCH37. In this instance, UCH37 bound to Smad3 and marginally to Smad2, however, we found a very strong interaction with Smad7 ( Figure 1b) . This difference in relative affinity between Smad2 and Smad3 could be explained by the presence of an additional exon in the N-terminal region that makes these R-Smads behave differently with respect to MH1 domain function. Based on a multialignment of Smad7 and Smad3, there are only a few stretches of very weak amino-acid sequence homology within the N-terminal region. One example is a -V-X-R-L-motif (where X is either lysine or arginine), at positions 12-15 in Smad3 that is also present in Smad7 (residues 10-13). However, this might be insufficient homology for a conserved interaction motif and, in any case, it is always difficult to predict with certainty since homology at structural level might be present in other regions that is not so apparent from primary structure.
The interaction of UCH37 with Smad7 is of particular interest since Smad7 has been shown to function as an adaptor that recruits the Smurf E3 ubiquitin ligase to the TGF-b receptor complex to promote its ubiquitination and proteasomal degradation. To identify the region in Smad7 that interacts with UCH37 we performed GST pull down experiments of full-length and truncated Smad7. Both full-length Smad7 and Smad7 1-260 , but not Smad7 260-426 , were able to efficiently pull Mouse UCH37/UCHL5 was identified as a positive and subsequently obtained as a full-length EST clone (EST clone 1197628), and subcloned into pCMV1-FLAG and pCMV1-HA. (b) Smad-GST fusion proteins were prepared and attached to glutathionesepharose beads as described previously (Wicks et al., 2000) . Immobilized proteins were then incubated with lysates from HEK-293 cells expressing HA-UCH37 and washed extensively before separation by SDS-10% PAGE and immunoblotting against anti-HA antibody. The presence of the GST fusion proteins was confirmed by staining gels with Coomassie Blue (C/Blue). (c) The following GST fusion proteins were prepared: full-length Smad7, Smad7 1-260 , full-length Smad7DPY, Smad7 1-260 DPY, and Smad7 260-426 . The DPY mutation involves changes of the proline to glycine and tyrosine to serine in the conserved ÀPYÀ motif. GST proteins immobilized to glutathione-sepharose beads were then incubated with lysates from HEK-293 cells expressing HA-UCH37, and washed extensively before separation by SDS-10% PAGE and immunoblotting against anti-HA antibody. The presence of the GST fusion proteins was confirmed by staining gels with C/Blue. The GST fusion proteins are indicated with an arrowhead
The deubiquitinating enzyme UCH37 regulates TGF-b signalling SJ Wicks et al down UCH37, and mutation of the -PY-motif in both Smad7 and Smad7 1-260 did not affect this interaction (Figure 1c) . Since the -PY-motif is required for the interaction of Smad7 with Smurf, we conclude that UCH37 is likely to bind to the N-terminal half of Smad7 in a region that is distinct from the Smurf binding site.
We then confirmed that Smad7 interacts with UCH37 endogenously in U4A/JAK1 cells. In the majority of cell types, the basal expression of Smad7 is low, however, its expression can be induced in U4A/JAK1 cells treated with interferon-g (Ulloa et al., 1999) . In cells stimulated with interferon-g for 2 h, Smad7 expression is induced and it also co-immunoprecipitates with endogenous UCH37 (Figure 2a ). No such complex was observed in the parental U4A cell line in which Smad7 is not induced by interferon-g (Figure 2a ; Ulloa et al., 1999) . Importantly, these results demonstrate that Smad7 and UCH37 associate at endogenous levels of expression. We then performed coexpression and co-immunoprecipitation studies of epitope-tagged proteins in HEK-293 cells. In these experiments, HA-tagged full length UCH37, or a truncation lacking a C-terminal extension downstream of the N-terminal enzymatic domain (UCH37DC; lacking residues Trp 196 -Lys 329 ), was coexpressed with FLAG-tagged Smad7 proteins. Here we found that Smad7 bound to both full-length UCH37 and UCH37DC both in the presence and absence of an activated type I TGF-b receptor (Figure 2b ). To identify whether Smad7 bound to UCH37 can form a complex with the type I TGF-b receptor we performed a co-immunoprecipitation using anti-FLAG antibody from HEK-293 cells transfected with FLAG-Smad-7, HA-UCH37 in the presence and absence of an activated type I TGF-b receptor. These data clearly suggest that UCH37 binds directly to Smad7 in a complex that includes the type I TGF-b receptor (Figure 2c) .
Next, we examined whether ubiquitination and stability of the type I TGF-b receptor were affected by UCH37. We coexpressed the type I TGF-b receptor together with Smad7, Smurf2 and increasing amounts of UCH37 in HEK-293 cells. In the presence of Smurf2, the levels of TGF-b type I receptors was significantly reduced, based on Western blotting of lysates, confirming that Smurf2 can destabilize the TGF-b type I receptor in a Smad7-dependent manner (Figure 2d ; left panel). However, coexpression of Smad7 and Smurf2 35 S-methionine] as described previously (Chantry, 1995 ). Pulse-chase was then applied for the indicated times and immunoprecipitations were performed using anti-type I TGF-b receptor antibody. Samples were separated by SDS-10% PAGE, and gels were dried and exposed to X-ray film together with increasing amounts of UCH37 led to a substantial stabilization of the TGF-b type I receptor (Figure 2d ; left panel). We then examined whether the TGF-b type I receptor is a direct substrate for UCH37 in vivo by cotransfection of HEK-293 cells with an activated TGF-b type I receptor, in the presence or absence of Smurf2 and UCH37 and together with HAtagged ubiquitin as well as Smad7. The degree of TGF-b type I receptor ubiquitination was then monitored by specific immunoprecipitation of the TGF-b type I receptor and probing of Western blots with anti-HA antibody. The amount of HA-ubiquitin incorporated into the TGF-b type I receptor was substantially increased in the presence of Smurf2, and this was reduced almost back to basal levels following coexpression of UCH37 (Figure 2d ; middle panel). The effect that deubiquitination of the type I TGF-b receptor by UCH37 has on receptor turnover was then analyzed by pulse-chase experiments. Acceleration of receptor turnover by Smurf2 and Smad7 was efficiently reversed in the presence of UCH37 (Figure 2d ; right panel).
Since UCH37 can stabilize the TGF-b type I receptor, we examined its effect on TGF-b-dependent transcriptional responses. In HEK-293 cells, the activated TGF-b type I receptor increased the activity of the Smad-specific CAGA12-luc transcriptional reporter (Figure 3a ). This effect was increased 2-3 fold in the presence of UCH37 and significantly attenuated by Smurf2; moreover, coexpression with UCH37 reversed the Smurf2-mediated inhibition almost back to levels seen in the presence of UCH37 alone (Figure 3a) . To further confirm the role of UCH37 in regulating TGF-b signalling, we examined the effect of an RNAi plasmid directed against endogenous UCH37. Transfection of HEK-293 cells with increasing amounts of the UCH37 RNAi plasmid reduced the expression of UCH37 by about 70% based on the densitometric scanning of Western blots relative to an internal b-actin control (Figure 3b) , and also abrogated TGF-b-dependent CAGA12 transcriptional activity to a similar extent (Figure 3c ). These functional effects on TGF-b signalling are not due to aberrant Smad7 subcellular localization since immunocytochemical experiments demonstrated that UCH37 did not compromise TGFb-dependent Smad7 nuclear export (data not shown).
In summary, we have identified a novel complex between Smad7 and the deubiquitinating enzyme UCH37. Subsequently, we have shown that this can lead to deubiquitination of the associated type I TGF-b receptor complex and thereby promote TGF-b signalling. Since Smad7 is required for both Smurf-and UCH37-mediated effects on the TGF-b receptor, it is difficult to assess the absolute dependence for Smad7 on UCH37 action. However, data presented throughout supports the notion that Smad7 and UCH37 act together to impact on type I TGF-b receptor function, and competes directly with the downregulating function of the Smurf family of E3 ubiquitin ligases. To our knowledge, this is also the first report of a role for UCH37 in the specific control of a cellular signalling pathway. Our present study now defines a novel intracellular mechanism that may function to stabilize or reactivate TGF-b signalling that has been repressed by the Smad7/Smurf complex. Alternatively, it may provide a mechanism for sustaining TGF-b signalling immediately following receptor activation. It will now be interesting to elucidate the mechanisms that determine the relative recruitment of Smurfs and UCH37 to the TGF-b receptor complex. Upregulation of TGF-b signalling by UCH37 could also be partly explained by the deubiquitination and stabilization of Smad3, and future experiments aim to clarify the physiological importance of the UCH37/Smad3 complex. We will also address the importance of other deubiquitinating enzymes in the regulation of Smad signalling, particularly, in the context of specificity relative to ubiquitination by distinct E3 ubiquitin ligases. In addition, it will be of great interest to develop in vitro assays to analyze the (a) HEK-293 were transiently transfected with 1 mg CAGA-12 luciferase reporter plasmid together with various combinations of FLAG-TGF-bRI T204D , FLAG-Smurf2 and FLAG-UCH37 as indicated. Cells were starved in medium containing 0.5% fetal calf serum and approximately 48 h after transfection luciferase activity was measured using the Luciferase Reporter Assay (Promega). (b) HEK-293 cells were transfected with 20 mg of a UCH37 RNAi plasmid obtained from the Nederlands Kanker Instituut (NKI) and Cancer Research UK. The RNAi construct is cloned in the pRETROSUPER vector and consists of a mixture of three RNAi's against UCH37 (Genbank accession number NM_015984). Cell lysates were immunoblotted against rabbit polyclonal anti-UCH37 antibody or anti-actin antibody. (c) In a separate experiment, HEK-293 cells were transfected with 1 mg CAGA-12 luciferase reporter plasmid together with 8 mg RNAi-UCH37 in the presence/ absence of FLAG-TGF-bRI T204D as indicated. After 48 h, luciferase activity was measured as described above precise kinetics of TGF-b receptor deubiquitination. Overall, it is likely that the balance between Smurfmediated ubiquitination and UCH37-mediated deubiquitination is critical for fine-tuning responses, and that alterations in this homeostatic mechanism could contribute to aberrant TGF-b signalling seen in tumorigenesis, fibrosis and many other human diseases.
